Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.

NCT Number	NCT07224360
Lead Sponsor	CSL Behring
Conditions	Sickle Cell Disease
Enrollment	63 participants
Start Date	2026-02-02
Primary Completion	2028-06-29 (estimated)
Study Completion	2028-06-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-05